NCT05150938 - A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE) | Biotech Hunter

Enrollment

5,737

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions

Treatment of Venous Thromboembolism in Cancer Patients

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

DRUG

Low molecular weight heparin (LMWH)

Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

DRUG

vitamin K antagonist (VKA)

Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

DRUG

other NOACs

Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.

Trial Locations (1)

Unknown

Swedish registries, Multiple Locations